Back to Search
MICHAEL CHER, MD
MD
Urology Physician
NPI: 1336187400IndividualAccepts Medicare
Specialties, Licenses & Credentials
Urology PhysicianPrimary
Urology
Code: 208800000X
4301065742(MI)
CMS Specialties
PrimaryUROLOGY
Education
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Class of 1986
Research & Publications (20)
Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.
PMID 16651608·Am J Pathol·2006
8-other
Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.
PMID 12788977·Proc Natl Acad Sci U S A·2003
7-preclinical
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
PMID 19447430·J Urol·2009
3-trial
Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?
PMID 18769612·Curr Oncol·2008
8-other
C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis.
PMID 18714401·Neoplasia·2008
7-preclinical
Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
PMID 18472961·Neoplasia·2008
7-preclinical
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.
PMID 18403754·Stem Cells·2008
8-other
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.
PMID 18337451·Mol Cancer Res·2008
8-other
Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner.
PMID 18324629·Int J Cancer·2008
8-other
Lycopene and soy isoflavones in the treatment of prostate cancer.
PMID 17927495·Nutr Cancer·2007
3-trial
Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.
PMID 17525276·Am J Pathol·2007
7-preclinical
Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction.
PMID 17445684·Urology·2007
7-preclinical
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
PMID 17440096·Cancer Res·2007
7-preclinical
Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging.
PMID 17075820·Prostate·2007
4-observational
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
PMID 16114056·Prostate·2006
7-preclinical
Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel.
PMID 16950615·Eur J Cancer·2006
8-other
Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
PMID 16618739·Cancer Res·2006
8-other
Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.
PMID 16381009·Int J Cancer·2006
7-preclinical
Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis.
PMID 17136575·Clin Exp Metastasis·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4100 JOHN R ST
DETROIT, MI 48201 - Phone
- (800) 527-6266
Quick Facts
- NPI
- 1336187400
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile